Health Canada Approves Nexstim NBS 6 System for Treatment of MDD
May 06 2024 - 2:00AM
Health Canada Approves Nexstim NBS 6 System for Treatment of MDD
Press release, Helsinki, 6 May 2024 at 9 AM
(EEST)
Health Canada Approves Nexstim NBS 6
System for Treatment of MDD
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company")
has received approval from Health Canada for the marketing and
commercial distribution of its NBS 6 system for the treatment of
Major Depressive Disorder (MDD).
Released in the EU and the United States in
2023, the NBS 6 is a new generation Nexstim system. The NBS 6 is
currently FDA-approved for the treatment of major depressive
disorder (MDD), and CE marked for the treatment of major depression
and chronic neuropathic pain. One of the unique features of the NBS
6 is its modular design that allows for expansions of system
capabilities over time.
Mikko Karvinen, CEO of Nexstim, comments: “We
have been happy with the progress made with the release of the NBS
6, and this Health Canada approval gets us one step further on our
commercial expansion journey. We continue to be actively present in
the Canadian market, working closely together with our local
distributor Canadian Health Solutions (CHS).”
Further information is available on the
website www.nexstim.com, or by
contacting:
Mikko Karvinen, CEO +358 50 326
4101 mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating
growth-oriented medical technology company. Our mission is to
enable personalized and effective diagnostics and therapies for
challenging brain diseases and disorders.
Nexstim has developed a world-leading
non-invasive brain stimulation technology for navigated
transcranial magnetic stimulation (nTMS) with highly sophisticated
3D navigation providing accurate and personalized targeting of the
TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on
commercialization of the Navigated Brain Stimulation (NBS) system.
The NBS System 5 is the only FDA cleared and CE marked navigated
TMS system for presurgical mapping of the speech and motor cortices
of the brain.
Nexstim’s Therapy Business markets and sells the
NBS System 6 which is FDA cleared for marketing and commercial
distribution for the treatment of major depressive disorder (MDD)
in the United States. In Europe, the NBS 6 system is CE marked for
the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North
Growth Market Finland.
For more information, please visit
www.nexstim.com
- Nexstim Plc_Press release_Canada approval_06052024_FINAL